Technical Analysis for CRGX - CARGO Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| 20 DMA Support | Bullish | -6.77% | |
| Multiple of Ten Bullish | Other | -6.77% | |
| Gapped Down | Weakness | -6.77% | |
| Multiple of Ten Bullish | Other | -6.13% | |
| Inside Day | Range Contraction | -6.13% | |
| 20 DMA Support | Bullish | -4.81% | |
| Multiple of Ten Bearish | Other | -4.81% |
| Alert | Time |
|---|---|
| Possible NR7 | about 8 hours ago |
| Possible Inside Day | about 8 hours ago |
| 10 DMA Resistance | about 10 hours ago |
| Fell Below 10 DMA | about 10 hours ago |
| Gap Down Partially Closed | about 11 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immune System Tumor Cancer Immunotherapy Gene Therapy Therapies For Cancer T Cells Antigen Cd22 Car T Cell Siglec
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immune System Tumor Cancer Immunotherapy Gene Therapy Therapies For Cancer T Cells Antigen Cd22 Car T Cell Siglec
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 33.92 |
| 52 Week Low | 13.14 |
| Average Volume | 329,608 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 22.99 |
| 20-Day Moving Average | 19.59 |
| 10-Day Moving Average | 19.83 |
| Average True Range | 1.46 |
| RSI (14) | 39.76 |
| ADX | 15.31 |
| +DI | 17.70 |
| -DI | 18.29 |
| Chandelier Exit (Long, 3 ATRs) | 17.83 |
| Chandelier Exit (Short, 3 ATRs) | 22.63 |
| Upper Bollinger Bands | 21.11 |
| Lower Bollinger Band | 18.07 |
| Percent B (%b) | 0.31 |
| BandWidth | 15.50 |
| MACD Line | -0.62 |
| MACD Signal Line | -0.86 |
| MACD Histogram | 0.241 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.18 | ||||
| Resistance 3 (R3) | 21.38 | 20.86 | 20.81 | ||
| Resistance 2 (R2) | 20.86 | 20.31 | 20.76 | 20.69 | |
| Resistance 1 (R1) | 19.93 | 19.96 | 19.67 | 19.73 | 20.57 |
| Pivot Point | 19.41 | 19.41 | 19.28 | 19.31 | 19.41 |
| Support 1 (S1) | 18.48 | 18.86 | 18.22 | 18.28 | 17.43 |
| Support 2 (S2) | 17.96 | 18.51 | 17.86 | 17.31 | |
| Support 3 (S3) | 17.03 | 17.96 | 17.19 | ||
| Support 4 (S4) | 16.83 |
